

Steven A Narod

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/381843/steven-a-narod-publications-by-year.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

438 papers	40,390 citations	83 h-index	195 g-index
467 ext. papers	45,382 ext. citations	7.4 avg, IF	7.04 L-index

#	Paper	IF	Citations
438	Platelet Count and Survival after Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	3
437	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation.. <i>Gynecologic Oncology</i> , 2022 ,	4.9	1
436	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period.. <i>JAMA Network Open</i> , 2022 , 5, e2141633	10.4	3
435	Risk of Second Primary Thyroid Cancer in Women with Breast Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	1
434	Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland.. <i>Hereditary Cancer in Clinical Practice</i> , 2022 , 20, 13	2.3	1
433	Common Variant in ALDH2 Modifies the Risk of Breast Cancer Among Carriers of the p.K3326* Variant in BRCA2.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100450	3.6	
432	Risk factors for psychological morbidity and the protective role of coping self-efficacy in young women with breast cancer early in diagnosis: a national multicentre cohort study.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	0
431	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. <i>Nutrients</i> , 2021 , 13,	6.7	4
430	Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4967-4973	3.1	2
429	Gene Sequencing for Pathogenic Variants Among Adults With Breast and Ovarian Cancer in the Caribbean. <i>JAMA Network Open</i> , 2021 , 4, e210307	10.4	5
428	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021 , 146, 30-47	7.5	15
427	The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. <i>Cancers</i> , 2021 , 13,	6.6	1
426	PALB2 mutations and prostate cancer risk and survival. <i>British Journal of Cancer</i> , 2021 , 125, 569-575	8.7	1
425	The risk of contralateral breast cancer: a SEER-based analysis. <i>British Journal of Cancer</i> , 2021 , 125, 601-610	8.7	4
424	An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. <i>Cancer</i> , 2021 , 127, 3183-3193	6.4	
423	Adjuvant olaparib - should all patients with breast cancer have genetic testing?. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 607-608	19.4	0
422	The relationship between the predicted risk of death and psychosocial functioning among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 177-189	4.4	2

421	Rapid Genetic Testing for BRCA1 and BRCA2 Mutations at the Time of Breast Cancer Diagnosis: An Observational Study. <i>Annals of Surgical Oncology</i> , 2021 , 28, 2219-2226	3.1	4
420	Blood cadmium levels as a marker for early lung cancer detection. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021 , 64, 126682	4.1	10
419	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021 , 153, 417-423	4	2
418	Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital. <i>Familial Cancer</i> , 2021 , 20, 103-110	3	3
417	Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 515-523	4.4	1
416	Bilateral Mastectomy in Women With Unilateral Breast Cancer: A Review. <i>JAMA Surgery</i> , 2021 , 156, 569-576	5.6	7
415	Recurrent Mutations in , , and in Polish Patients with Ovarian Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
414	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , 2021 , 124, 1524-1532	8.7	2
413	Incidence of Cancer Among Adults With Thrombocytosis in Ontario, Canada. <i>JAMA Network Open</i> , 2021 , 4, e2120633	10.4	4
412	Genetic predisposition to male breast cancer in Poland. <i>BMC Cancer</i> , 2021 , 21, 975	4.8	0
411	Weight Gain and the Risk of Ovarian Cancer in and Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 2038-2043	4	1
410	Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer. <i>Cancer Research Communications</i> , 2021 , 1, 140-147		
409	Mammography screening for breast cancer-the UK Age trial. <i>Lancet Oncology, The</i> , 2020 , 21, e508	21.7	
408	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among and mutation carriers. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 825-830	3.5	1
407	Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. <i>British Journal of Cancer</i> , 2020 , 123, 268-274	8.7	11
406	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , 2020 , 147, 1245-1251	7.5	4
405	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , 2020 , 27, 1396-1402	2.5	5
404	BRCA1 promoter methylation in peripheral blood is associated with the risk of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2020 , 146, 1293-1298	7.5	12

403	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020 , 27, 156-161	2.5	3
402	Late Recurrences After Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020 , 6, 301-302	13.4	1
401	Retesting of women who are negative for a and mutation using a 20-gene panel. <i>Journal of Medical Genetics</i> , 2020 , 57, 380-384	5.8	5
400	Preferences for breast cancer prevention among women with a or mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2020 , 18, 20	2.3	1
399	Survival Differences in Chinese Versus White Women With Breast Cancer in the United States: A SEER-Based Analysis. <i>JCO Global Oncology</i> , 2020 , 6, 1582-1592	3.7	3
398	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020 , 159, 820-826	4.9	3
397	Assessment of Secondary Sarcomas Among Patients With Cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone. <i>JAMA Network Open</i> , 2020 , 3, e2013929	10.4	1
396	In Response to "Pregnancy After Breast Cancer in Patients With Germline Mutations". <i>Journal of Clinical Oncology</i> , 2020 , 38, 4352	2.2	0
395	Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. <i>British Journal of Cancer</i> , 2020 , 123, 1608-1615	8.7	1
394	Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. <i>Cancers</i> , 2020 , 12,	6.6	7
393	Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. <i>International Journal of Cancer</i> , 2020 , 147, 2793-2800	7.5	8
392	Blood arsenic levels and the risk of familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2020 , 146, 2721-2727	7.5	9
391	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the NursesPHHealth Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1264-1270	4	4
390	Association Between Invasive Lobular Breast Cancer and Mutations in the Mismatch Repair Gene MSH6. <i>JAMA Oncology</i> , 2019 , 5, 120	13.4	0
389	Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 629-636	4.4	1
388	MRI versus mammography for breast cancer screening in women with familial risk (FaMRisc). <i>Lancet Oncology</i> , 2019 , 20, e465	21.7	2
387	Inherited variants in XRCC2 and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 657-663	4.4	6
386	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. <i>Gynecologic Oncology</i> , 2019 , 155, 270-274	4.9	6

385	Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. <i>British Journal of Cancer</i> , 2019 , 120, 398-403	8.7	13
384	The spectrum of mutations predisposing to familial breast cancer in Poland. <i>International Journal of Cancer</i> , 2019 , 145, 3311-3320	7.5	24
383	is A Low/Moderate Breast Cancer Risk Gene: Evidence Based on An Association Study of the Central European p.Q564X Recurrent Mutation. <i>Cancers</i> , 2019 , 11,	6.6	18
382	Gender bias in CIHR Foundation grant awarding. <i>Lancet, The</i> , 2019 , 393, 2195	4.0	1
381	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2019 , 121, 15-21	8.7	50
380	Author response to "a response to personalised medicine and population health: breast and ovarian cancer". <i>Human Genetics</i> , 2019 , 138, 291-292	6.3	0
379	Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a BRCA Mutation. <i>JAMA Network Open</i> , 2019 , 2, e198420	10.4	9
378	Allelic modification of breast cancer risk in women with an NBN mutation. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 427-431	4.4	5
377	Countercurrents: Is now the right time to pull the plug on mammography?. <i>Current Oncology</i> , 2019 , 26, 162-163	2.8	1
376	Predictors of mammographic density among women with a strong family history of breast cancer. <i>BMC Cancer</i> , 2019 , 19, 631	4.8	3
375	A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. <i>Breast Cancer Research and Treatment</i> , 2019 , 177, 691-703	4.4	5
374	Inherited Variants in and the Risk and Clinical Characteristics of Breast Cancer. <i>Cancers</i> , 2019 , 11,	6.6	1
373	Exome Sequencing in and -Negative Greek Families Identifies and as Candidate Risk Genes for Hereditary Breast Cancer. <i>Frontiers in Genetics</i> , 2019 , 10, 1005	4.5	7
372	Plasma RANKL levels are not associated with breast cancer risk in and mutation carriers. <i>Oncotarget</i> , 2019 , 10, 2475-2483	3.3	5
371	CHEK2 Alleles Predispose to Renal Cancer in Poland. <i>JAMA Oncology</i> , 2019 , 5, 576	13.4	6
370	The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. <i>Cancer</i> , 2019 , 125, 2130	6.4	0
369	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 443-449	4.4	7
368	Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2019 , 152, 145-150	4.9	23

367	Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 741-748	4.4	10
366	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 769-774	4.4	4
365	Predictors of time to death after distant recurrence in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019 , 173, 465-474	4.4	12
364	A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 469-477	4.4	6
363	Reply to Hollingsworth: does breast cancer metastasize in the clinical window between the mammogram and the mass?. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 639-640	4.4	1
362	Serum osteoprotegerin levels and mammographic density among high-risk women. <i>Cancer Causes and Control</i> , 2018 , 29, 507-517	2.8	5
361	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. <i>JAMA Oncology</i> , 2018 , 4, 1059-1065	13.4	84
360	Genetic testing for young women with breast cancer. <i>Lancet Oncology</i> , 2018 , 19, e182	21.7	1
359	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 561-571	4.4	19
358	Is There a Future for Ovarian Cancer Screening?. <i>JAMA Internal Medicine</i> , 2018 , 178, 611-612	11.5	2
357	A comparison of two models for breast cancer mortality for women with ductal carcinoma in situ: an SEER-based analysis. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 587-594	4.4	3
356	Is invasion a necessary step for metastases in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 9-23	4.4	34
355	Short report: Follow-up of Bahamian women with a BRCA1 or BRCA2 mutation. <i>Molecular Genetics & Genomic Medicine</i> , 2018 , 6, 301-304	2.3	4
354	Predictors of survival for breast cancer patients with a BRCA1 mutation. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 513-521	4.4	12
353	The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2018 , 142, 2263-2272	7.5	14
352	Frequency of and causative founder variants in ovarian cancer patients in South-East Poland. <i>Hereditary Cancer in Clinical Practice</i> , 2018 , 16, 6	2.3	3
351	The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 170, 647-656	4.4	61
350	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018 , 47, 987-997	7.8	6

349	Serum selenium levels predict survival after breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 591-598	4.4	23
348	The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 263-267	4.4	27
347	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	3
346	Serum selenium levels and the risk of progression of laryngeal cancer. <i>PLoS ONE</i> , 2018 , 13, e0184873	3.7	17
345	Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 709-717	4.4	7
344	The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer. <i>Clinical Genetics</i> , 2018 , 93, 1063-1068	4	9
343	Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. <i>Breast Cancer Research and Treatment</i> , 2018 , 167, 787-795	4.4	40
342	Population-Based Genetic Testing for BRCA1 and BRCA2. <i>Journal of Clinical Oncology</i> , 2018 , 36, 517	2.2	4
341	Computer-Assisted Flagging of Individuals at High Risk of Colorectal Cancer in a Large Health Maintenance Organization Using the ColonFlag Test. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-8	5.2	7
340	Prediction of findings at screening colonoscopy using a machine learning algorithm based on complete blood counts (ColonFlag). <i>PLoS ONE</i> , 2018 , 13, e0207848	3.7	9
339	Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy. <i>JAMA Oncology</i> , 2018 , 4, 1620	13.4	
338	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , 2018 , 119, 1421-1427	8.7	7
337	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. <i>Cancer Prevention Research</i> , 2018 , 11, 697-706	3.2	33
336	Reply to R Mutations in RECQL are not associated with breast cancer risk in an Australian population? <i>Nature Genetics</i> , 2018 , 50, 1348-1349	36.3	1
335	Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US. <i>Clinical Epidemiology</i> , 2018 , 10, 1349-1358	5.9	5
334	Personalised medicine and population health: breast and ovarian cancer. <i>Human Genetics</i> , 2018 , 137, 769-778	6.3	25
333	Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1787-1788	13.4	
332	Time to death in breast cancer patients as an indicator of treatment response. <i>Breast Cancer Research and Treatment</i> , 2018 , 172, 659-669	4.4	12

331	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2018 , 150, 85-91	4.9	47
330	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 421-426	4.4	8
329	Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2. <i>JAMA Oncology</i> , 2018 , 4, 1012	13.4	3
328	The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. <i>British Journal of Cancer</i> , 2018 , 118, 1399-1405	8.7	5
327	Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2017 , 116, 964-971	8.7	34
326	Association of the Timing of Pregnancy With Survival in Women With Breast Cancer. <i>JAMA Oncology</i> , 2017 , 3, 659-665	13.4	57
325	Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens. <i>Familial Cancer</i> , 2017 , 16, 351-355	3	13
324	Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records. <i>British Journal of Cancer</i> , 2017 , 116, 944-950	8.7	7
323	A high frequency of PALB2 mutations in Jamaican patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 591-596	4.4	6
322	Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2017 , 5, e1281	1.2	3
321	Estimating the effect of immortal-time bias in urological research: a case example of testosterone-replacement therapy. <i>BJU International</i> , 2017 , 120, 584-590	5.6	3
320	The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 391-402	4.4	21
319	Which women decide to take tamoxifen?. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 149-155	4.4	5
318	Response. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	3
317	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , 2017 , 145, 346-351	4.9	23
316	A Population-Based Cross-Sectional Study Comparing Breast Cancer Stage at Diagnosis between Immigrant and Canadian-Born Women in Ontario. <i>Breast Journal</i> , 2017 , 23, 525-536	1.2	7
315	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1260-1271	27.4	21
314	Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer. <i>PLoS ONE</i> , 2017 , 12, e0171759	3.7	26

313	Reply to Kopans. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 653-654	4.4	1
312	Breast Cancer Genetics for Plastic Surgeons. <i>Plastic and Reconstructive Surgery</i> , 2017 , 140, 455-460	2.7	3
311	Functionally Null Missense Mutation Associates Strongly with Ovarian Carcinoma. <i>Cancer Research</i> , 2017 , 77, 4517-4529	10.1	18
310	Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 433-444	4.4	23
309	Mutation Frequencies in Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , 2017 , 3, 1586-1587	3.4	
308	Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2017 , 15, 4	2.3	11
307	The impact of nodal micrometastasis on mortality among women with early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 103-115	4.4	12
306	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 11-16	4.4	21
305	Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 135-142	4.4	25
304	Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	99
303	Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. <i>Familial Cancer</i> , 2017 , 16, 29-34	3	13
302	The impact of an expanded genetic testing program and selective oophorectomy on the incidence of ovarian cancer in West Pomerania. <i>Clinical Genetics</i> , 2017 , 91, 322-327	4	3
301	RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	0
300	Genetic testing for BRCA1 and BRCA2 in the Province of Ontario. <i>Clinical Genetics</i> , 2016 , 89, 304-11	4	14
299	Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. <i>Clinical Genetics</i> , 2016 , 89, 328-31	4	18
298	Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2016 , 115, 776-83	8.7	27
297	Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. <i>BMJ, The</i> , 2016 , 352, i851	5.9	126
296	Common genetic susceptibility to DCIS and invasive ductal carcinoma. <i>Breast Cancer Research</i> , 2016 , 18, 60	8.3	

295	Response to Evans et al. <i>Clinical Genetics</i> , 2016 , 89, 400	4	
294	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 365-73	4.4	43
293	Can advanced-stage ovarian cancer be cured?. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 255-61	19.4	192
292	Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression. <i>Cancer Prevention Research</i> , 2016 , 9, 83-8	3.2	8
291	Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. <i>Gynecologic Oncology</i> , 2016 , 140, 42-7	4.9	64
290	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016 , 105, 781-785	4.8	28
289	The relationship between local recurrence and death in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 175-85	4.4	26
288	New Rates of Interventions to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>European Urology</i> , 2016 , 69, 933-41	10.2	11
287	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	65
286	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2016 , 7, 86687-86694	3.3	25
285	A Matched Case-Control Study of Risk Factors for Breast Cancer Risk in Vietnam. <i>International Journal of Breast Cancer</i> , 2016 , 2016, 7164623	2.3	12
284	Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 385-93	4.4	4
283	A model for ovarian cancer progression based on inherent resistance. <i>Gynecologic Oncology</i> , 2016 , 142, 484-9	4.9	8
282	Hospitalizations to Manage Complications of Modern Prostate Cancer Treatment in Older Men. <i>Urology</i> , 2016 , 96, 142-147	1.6	3
281	The risk of contralateral breast cancer in daughters of women with and without breast cancer. <i>Clinical Genetics</i> , 2016 , 89, 332-5	4	7
280	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 498-506	18.1	101
279	DCIS and invasive interval breast cancer. <i>Lancet Oncology, The</i> , 2016 , 17, e87-e88	21.7	2
278	The incidence of bone metastasis after early-stage breast cancer in Canada. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 587-595	4.4	37

277	The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 371-8	4.4	11
276	Germline RECQL mutations in high risk Chinese breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016 , 157, 211-215	4.4	20
275	Low-grade serous ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2016 , 143, 433-438	4.9	92
274	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. <i>Breast Cancer Research</i> , 2016 , 18, 87	8.3	6
273	Response to Comments on The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. <i>British Journal of Cancer</i> , 2016 , 115, e4	8.7	
272	Cardiovascular and Skeletal-related Events Following Localized Prostate Cancer Treatment: Role of Surgery, Radiotherapy, and Androgen Deprivation. <i>Urology</i> , 2016 , 97, 145-152	1.6	17
271	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. <i>American Journal of Clinical Nutrition</i> , 2016 , 104, 671-7	7	17
270	CHEK2 mutations and the risk of papillary thyroid cancer. <i>International Journal of Cancer</i> , 2015 , 137, 548-552	7.5	75
269	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 71-80	4.4	74
268	Thyroid hormone receptor β in breast cancer: prognostic and therapeutic implications. <i>Breast Cancer Research and Treatment</i> , 2015 , 149, 293-301	4.4	25
267	The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 389-94	4.4	49
266	Re: Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	0
265	Why have breast cancer mortality rates declined?. <i>Journal of Cancer Policy</i> , 2015 , 5, 8-17	1	80
264	Re: Pan-Canadian study of mammography screening and mortality from breast cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	3
263	Why have ovarian cancer mortality rates declined? Part I. Incidence. <i>Gynecologic Oncology</i> , 2015 , 138, 741-9	4.9	62
262	Why have ovarian cancer mortality rates declined? Part II. Case-fatality. <i>Gynecologic Oncology</i> , 2015 , 138, 750-6	4.9	38
261	Why have ovarian cancer mortality rates declined? Part III. Prospects for the future. <i>Gynecologic Oncology</i> , 2015 , 138, 757-61	4.9	24
260	Germline RECQL mutations are associated with breast cancer susceptibility. <i>Nature Genetics</i> , 2015 , 47, 643-6	36.3	123

259	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>JAMA Oncology</i> , 2015 , 1, 306-13	13.4	81
258	Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study. <i>Familial Cancer</i> , 2015 , 14, 383-91	3	23
257	Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry. <i>Breast Cancer Research and Treatment</i> , 2015 , 150, 637-41	4.4	
256	Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. <i>Lancet Oncology</i> , 2015 , 16, 638-44	21.7	106
255	Complications following surgery with or without radiotherapy or radiotherapy alone for prostate cancer. <i>British Journal of Cancer</i> , 2015 , 112, 977-82	8.7	22
254	A model for estimating ovarian cancer risk: application for preventive oophorectomy. <i>Gynecologic Oncology</i> , 2015 , 139, 242-7	4.9	8
253	Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1315-26	3.5	36
252	Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 163-9	4.4	4
251	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015 , 15, 668-79	31.3	581
250	Germline TP53 mutational spectrum in French Canadians with breast cancer. <i>BMC Medical Genetics</i> , 2015 , 16, 24	2.1	15
249	A prospective study of mastectomy patients with and without delayed breast reconstruction: long-term psychosocial functioning in the breast cancer survivorship period. <i>Journal of Surgical Oncology</i> , 2015 , 111, 258-64	2.8	25
248	Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2015 , 1, 888-96	13.4	330
247	CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015 Still in the Ballpark. <i>Clinical Cancer Research</i> , 2015 , 21, 3813-4	12.9	9
246	Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2015 , 137, 1136-46	7.5	44
245	Genetic testing for RAD51C mutations: in the clinic and community. <i>Clinical Genetics</i> , 2015 , 88, 303-12	4	32
244	Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. <i>Clinical Genetics</i> , 2015 , 88, 366-70	4	33
243	Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. <i>Clinical Chemistry</i> , 2015 , 61, 239-48	5.5	35
242	Recurrent BRCA1 and BRCA2 mutations in Mexican women with breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 498-505	4	24

241	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. <i>Clinical Genetics</i> , 2015 , 88, 371-5	4	39
240	BRCA1 and BRCA2 mutations and the risk for colorectal cancer. <i>Clinical Genetics</i> , 2015 , 87, 411-8	4	58
239	Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas. <i>Clinical Genetics</i> , 2015 , 88, 182-6	4	15
238	Recurrent mutations of BRCA1 and BRCA2 in Poland: an update. <i>Clinical Genetics</i> , 2015 , 87, 288-92	4	26
237	Prostate cancer in a man with a BRCA2 mutation and a personal history of bilateral breast cancer. <i>Clinical Genetics</i> , 2015 , 88, 187-9	4	1
236	Counterpoint re: "Mammography screening-sticking to the science". <i>Current Oncology</i> , 2015 , 22, 177	2.8	5
235	Identification and Validation of a Five MicroRNA Signature Predictive of Prostate Cancer Recurrence and Metastasis: A Cohort Study. <i>Journal of Cancer</i> , 2015 , 6, 1160-71	4.5	26
234	Risk Factors for Premenopausal Breast Cancer in Bangladesh. <i>International Journal of Breast Cancer</i> , 2015 , 2015, 612042	2.3	7
233	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2015 , 151, 435-41	4.4	8
232	Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 165-73	27.4	356
231	Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis. <i>Urology</i> , 2015 , 85, 621-7	1.6	21
230	The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. <i>Cancer Causes and Control</i> , 2015 , 26, 333-44	2.8	34
229	The effect of oral 3,3Pdiindolylmethane supplementation on the 2:16EOHE ratio in BRCA1 mutation carriers. <i>Familial Cancer</i> , 2015 , 14, 281-6	3	5
228	Survival from breast cancer in patients with CHEK2 mutations. <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 397-403	4.4	9
227	Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 579-86	4.4	53
226	Bilateral breast cancers. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 157-66	19.4	43
225	Modes of delivery of genetic testing services and the uptake of cancer risk management strategies in BRCA1 and BRCA2 carriers. <i>Clinical Genetics</i> , 2014 , 85, 49-53	4	25
224	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. <i>British Journal of Cancer</i> , 2014 , 110, 530-4	8.7	95

223	BRCA1 mRNA levels following a 4-6-week intervention with oral 3,3Pdiindolylmethane. <i>British Journal of Cancer</i> , 2014 , 111, 1269-74	8.7	17
222	Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014 , 148, 615-22	4.4	28
221	The authors reply. <i>American Journal of Epidemiology</i> , 2014 , 180, 760-1	3.8	1
220	The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 462-7	4.9	73
219	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1547-53	2.2	397
218	Telomere length and mortality following a diagnosis of ovarian cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2603-6	4	20
217	Modern approaches to cancer prevention: Universal or personal?. <i>Journal of Cancer Policy</i> , 2014 , 2, 93-96		
216	Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 113-8	4.4	19
215	Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. <i>SpringerPlus</i> , 2014 , 3, 295		4
214	Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2014 , 147, 401-5	4.4	186
213	Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 421-7	4.4	29
212	BRCA1 founder mutations compared to ovarian cancer in Belarus. <i>Familial Cancer</i> , 2014 , 13, 445-7	3	4
211	Genetics of endometrial cancer. <i>Familial Cancer</i> , 2014 , 13, 499-505	3	11
210	Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers?. <i>Gynecologic Oncology</i> , 2014 , 134, 219-21	4.9	5
209	Screening for BRCA1 and BRCA2 mutations among French-Canadian breast cancer cases attending an outpatient clinic in Montreal. <i>Clinical Genetics</i> , 2014 , 85, 31-5	4	11
208	Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers. <i>Clinical Genetics</i> , 2014 , 85, 68-71	4	15
207	Factors associated with breast cancer mortality after local recurrence. <i>Current Oncology</i> , 2014 , 21, e418-25		25
206	The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2014 , 111, 1238-40	8.7	48

205	A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. <i>Current Oncology</i> , 2014 , 21, 64-8	2.8	8
204	Multiple primary cancers as a guide to heritability. <i>International Journal of Cancer</i> , 2014 , 135, 1756-63	7.5	31
203	Preventing ovarian cancer through genetic testing: a population-based study. <i>Clinical Genetics</i> , 2014 , 86, 496-9	4	15
202	The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. <i>Clinical Genetics</i> , 2014 , 85, 64-7	4	46
201	PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt323	9.7	26
200	Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. <i>BMJ, The</i> , 2014 , 348, g226	5.9	181
199	Multiple therapeutic and preventive effects of 3,3Pdiindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. <i>Journal of Biomedical Research</i> , 2014 , 28, 339-48	1.5	14
198	Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. <i>Lancet Oncology, The</i> , 2014 , 15, 223-31	21.7	155
197	Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , 2014 , 85, 21-30	4	13
196	Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. <i>Clinical Genetics</i> , 2014 , 85, 72-5	4	6
195	The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. <i>Psycho-Oncology</i> , 2013 , 22, 212-9	3.9	63
194	Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , 2013 , 84, 43-6	4	13
193	The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. <i>Prostate</i> , 2013 , 73, 542-8	4.2	29
192	A common nonsense mutation of the BLM gene and prostate cancer risk and survival. <i>Gene</i> , 2013 , 532, 173-6	3.8	20
191	Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3191-6	2.2	92
190	Clinical characteristics of breast cancer in patients with an NBS1 mutation. <i>Breast Cancer Research and Treatment</i> , 2013 , 141, 471-6	4.4	2
189	Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 375-84	4.4	15
188	Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers. <i>Familial Cancer</i> , 2013 , 12, 615-9	3	3

187	The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. <i>Breast Cancer Research and Treatment</i> , 2013 , 142, 177-85	4.4	40
186	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 141-8	9.7	107
185	The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. <i>Gynecologic Oncology</i> , 2013 , 130, 127-31	4.9	83
184	The risk of gastric cancer in carriers of CHEK2 mutations. <i>Familial Cancer</i> , 2013 , 12, 473-8	3	34
183	Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2013 , 99, 1724-8	4.8	90
182	Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. <i>Clinical Genetics</i> , 2013 , 83, 88-91	4	14
181	Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. <i>Clinical Genetics</i> , 2013 , 83, 232-7	4	12
180	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , 2013 , 5, 31	1.2	
179	International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3817-22	3.1	23
178	Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 155-61	4.4	48
177	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 273-9	4.4	25
176	Breast cancer and the environment: what is left to learn?: A Countercurrents Series. <i>Current Oncology</i> , 2013 , 20, 8-9	2.8	3
175	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
174	An inherited NBN mutation is associated with poor prognosis prostate cancer. <i>British Journal of Cancer</i> , 2013 , 108, 461-8	8.7	67
173	A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. <i>British Journal of Cancer</i> , 2013 , 109, 777-9	8.7	24
172	A low selenium level is associated with lung and laryngeal cancers. <i>PLoS ONE</i> , 2013 , 8, e59051	3.7	39
171	Ten types of breast cancer?. <i>Lancet, The</i> , 2012 , 380, 1212-3	4.0	2
170	Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers. <i>Obesity</i> , 2012 , 20, 1288-92	8	8

169	Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012 , 14, R42	8.3	68
168	Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2012 , 14, R110	8.3	151
167	Tumour characteristics among women with very low-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 1241-6	4.4	11
166	Androgens and breast cancer. <i>Steroids</i> , 2012 , 77, 1-9	2.8	52
165	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. <i>Cancer Treatment Reviews</i> , 2012 , 38, 318-28	14.4	67
164	The R337H mutation in TP53 and breast cancer in Brazil. <i>Hereditary Cancer in Clinical Practice</i> , 2012 , 10, 3	2.3	23
163	Breast cancer in young women. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 460-70	19.4	125
162	BRCA1 and BRCA2 mutations among familial breast cancer patients from Costa Rica. <i>Clinical Genetics</i> , 2012 , 82, 484-8	4	21
161	BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. <i>Women's Health</i> , 2012 , 8, 543-55	3	61
160	Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. <i>Annals of Surgical Oncology</i> , 2012 , 19, 233-41	3.1	76
159	The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. <i>International Journal of Cancer</i> , 2012 , 131, 229-34	7.5	33
158	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012 , 23, 1065-74	2.8	19
157	Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 735-40	4.4	69
156	The tip of the iceberg: a countercurrents series. <i>Current Oncology</i> , 2012 , 19, 129-30	2.8	3
155	Tumour size predicts long-term survival among women with lymph node-positive breast cancer. <i>Current Oncology</i> , 2012 , 19, 249-53	2.8	39
154	A model for breast cancer risk based on stem-cell theory. <i>Current Oncology</i> , 2012 , 19, 9-11	2.8	8
153	Disappearing breast cancers. <i>Current Oncology</i> , 2012 , 19, 59-60	2.8	18
152	Choices for young women at intermediate risk of breast cancer. <i>Current Oncology</i> , 2012 , 19, e112-4	2.8	

151	Are bilateral cancers hereditary? Part II. <i>Current Oncology</i> , 2012 , 19, 246-7	2.8	1
150	Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1089-96	4	39
149	BRCA1 haploinsufficiency: consequences for breast cancer. <i>Women's Health</i> , 2012 , 8, 127-9	3	13
148	Hormone replacement therapy and the risk of breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 669-76	19.4	99
147	Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. <i>Maturitas</i> , 2011 , 70, 261-5	5	57
146	Genetic variants associated with breast-cancer risk. <i>Lancet Oncology</i> , 2011 , 12, 415-6	21.7	7
145	Earlier age of onset in BRCA carriers-anticipation or cohort effect?: A Countercurrents Series. <i>Current Oncology</i> , 2011 , 18, 257-8	2.8	6
144	Early-onset breast cancer: what do we know about the risk factors?: A Countercurrents Series. <i>Current Oncology</i> , 2011 , 18, 204-5	2.8	9
143	Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2011 , 104, 1384-92	8.7	167
142	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 121, 353-7	4.9	280
141	Screening of women at high risk for breast cancer. <i>Preventive Medicine</i> , 2011 , 53, 127-30	4.3	11
140	A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 591-6	4.4	55
139	Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 259-66	4.4	25
138	Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 287-96	4.4	66
137	The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 581-3	4.4	23
136	Mutations in Fanconi anemia genes and the risk of esophageal cancer. <i>Human Genetics</i> , 2011 , 129, 573-82	3.3	35
135	Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. <i>Cancer</i> , 2011 , 117, 1812-8	6.4	49
134	Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3747-52	2.2	157

133	The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. <i>Canadian Urological Association Journal</i> , 2011 , 5, E31-5	1.2	12
132	Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families?. <i>Clinical Genetics</i> , 2010 , 77, 273-9	4	12
131	Testing for CHEK2 in the cancer genetics clinic: ready for prime time?. <i>Clinical Genetics</i> , 2010 , 78, 1-7	4	45
130	The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. <i>Clinical Genetics</i> , 2010 , 78, 373-6	4	25
129	The contribution of founder mutations in BRCA1 to breast cancer in Belarus. <i>Clinical Genetics</i> , 2010 , 78, 377-80	4	21
128	Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. <i>Clinical Genetics</i> , 2010 , 78, 411-7	4	42
127	Personalized medicine: a personal view. <i>Current Oncology</i> , 2010 , 17, 4-5	2.8	1
126	Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. <i>Journal of Clinical Oncology</i> , 2010 , 28, 387-91	2.2	141
125	Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1874-8	9.7	74
124	Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation. <i>Journal of Clinical Oncology</i> , 2010 , 28, e698-9; author reply e700	2.2	11
123	BRCA mutations in the management of breast cancer: the state of the art. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 702-7	19.4	125
122	Genes, the environment, and breast cancer. <i>Lancet, The</i> , 2010 , 375, 2123-4	40	8
121	Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 375-9	2.2	417
120	BRCA1 and BRCA2 families and the risk of skin cancer. <i>Familial Cancer</i> , 2010 , 9, 489-93	3	25
119	BRCA1 mutations and colorectal cancer in Poland. <i>Familial Cancer</i> , 2010 , 9, 541-4	3	20
118	Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation. <i>Gynecologic Oncology</i> , 2010 , 118, 155-9	4.9	21
117	Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2010 , 118, 295-8	4.9	24
116	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2009 , 115, 135-137	4.9	12

115	Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. <i>Cancer</i> , 2009 , 115, 4917-23	6.4	44
114	Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery. <i>Cancer</i> , 2009 , 115, 5780-7	6.4	68
113	Mutations of the MYH gene do not substantially contribute to the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 575-8	4.4	27
112	Pattern of metastatic spread in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 423-8	4.4	369
111	Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 359-63	4.4	266
110	Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 131-7	4.4	79
109	Germline RAP80 mutations and susceptibility to breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 113, 377-81	4.4	16
108	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 127-35	4.4	23
107	The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. <i>Familial Cancer</i> , 2009 , 8, 563-7	3	29
106	Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2009 , 100, 421-5	8.7	85
105	Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. <i>Clinical Genetics</i> , 2009 , 75, 72-8	4	41
104	The contribution of founder mutations to early-onset breast cancer in French-Canadian women. <i>Clinical Genetics</i> , 2009 , 76, 421-6	4	37
103	Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. <i>Human Molecular Genetics</i> , 2009 , 18, 1332-42	5.6	112
102	Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. <i>Salud Publica De Mexico</i> , 2009 , 51 Suppl 2, s191-6	1.7	12
101	Rapid progression of prostate cancer in men with a BRCA2 mutation. <i>British Journal of Cancer</i> , 2008 , 99, 371-4	8.7	112
100	Fusion in the ETS gene family and prostate cancer. <i>British Journal of Cancer</i> , 2008 , 99, 847-51	8.7	47
99	Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. <i>Clinical Genetics</i> , 2008 , 73, 474-9	4	42
98	Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1361-7	9.7	152

97	BRCA1 mutations and prostate cancer in Poland. <i>European Journal of Cancer Prevention</i> , 2008 , 17, 62-6	2	29
96	Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 289-96	4.4	120
95	Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 581-4	4.4	30
94	Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 585-93	4.4	49
93	Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. <i>Cancer Causes and Control</i> , 2008 , 19, 1111-9	2.8	63
92	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. <i>Familial Cancer</i> , 2008 , 7, 275-9	3	28
91	International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2008 , 122, 2017-22	7.5	268
90	Triple-negative breast cancer: clinical features and patterns of recurrence. <i>Clinical Cancer Research</i> , 2007 , 13, 4429-34	12.9	2961
89	Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?. <i>European Journal of Human Genetics</i> , 2007 , 15, 237-41	5.3	49
88	A survey of preventive measures among BRCA1 mutation carriers from Poland. <i>Clinical Genetics</i> , 2007 , 71, 153-7	4	9
87	A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 119-22	4.4	91
86	Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. <i>Breast Cancer Research and Treatment</i> , 2007 , 103, 349-53	4.4	59
85	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 221-8	4.4	38
84	CYP1B1 and predisposition to breast cancer in Poland. <i>Breast Cancer Research and Treatment</i> , 2007 , 106, 383-8	4.4	16
83	Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. <i>New England Journal of Medicine</i> , 2007 , 357, 115-23	59.2	230
82	Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 572-6	4	20
81	Ovarian cancer and HRT in the Million Women Study. <i>Lancet, The</i> , 2007 , 369, 1667-8	40	6
80	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology, The</i> , 2007 , 8, 26-34	21.7	186

79	Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. <i>Breast Cancer Research</i> , 2007 , 9, R83	8.3	110
78	Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. <i>Open Medicine</i> , 2007 , 1, e92-8		16
77	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. <i>Gynecologic Oncology</i> , 2006 , 100, 58-64	4.9	297
76	Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Gynecologic Oncology</i> , 2006 , 100, 83-8	4.9	34
75	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. <i>International Journal of Cancer</i> , 2006 , 118, 2281-4	7.5	220
74	The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. <i>Carcinogenesis</i> , 2006 , 27, 599-605	4.6	29
73	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 185-92	27.4	466
72	CHEK2-positive breast cancers in young Polish women. <i>Clinical Cancer Research</i> , 2006 , 12, 4832-5	12.9	30
71	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1694-706	9.7	486
70	Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Lancet Oncology</i> , 2006 , 7, 402-6	21.7	80
69	Regarding the use of tamoxifen post-oophorectomy to prevent hereditary breast cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2006 , 4, 167-8	2.3	
68	Modifiers of risk of hereditary breast cancer. <i>Oncogene</i> , 2006 , 25, 5832-6	9.2	88
67	Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 105-9	4.4	71
66	Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. <i>Breast Cancer Research and Treatment</i> , 2006 , 98, 285-94	4.4	93
65	BRCA1-positive breast cancers in young women from Poland. <i>Breast Cancer Research and Treatment</i> , 2006 , 99, 71-6	4.4	38
64	Direct-to-patient BRCA1 testing: the Twoj Styl experience. <i>Breast Cancer Research and Treatment</i> , 2006 , 100, 239-45	4.4	23
63	Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7804-10	2.2	339
62	Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2005 , 7, R833-43	8.3	80

61	Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. <i>International Journal of Cancer</i> , 2005 , 117, 988-91	7.5	131
60	The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. <i>Familial Cancer</i> , 2005 , 4, 97-103	3	71
59	Breast cancer predisposing alleles in Poland. <i>Breast Cancer Research and Treatment</i> , 2005 , 92, 19-24	4.4	104
58	Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Cancer Causes and Control</i> , 2005 , 16, 667-74	2.8	64
57	A comparison of bilateral breast cancers in BRCA carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005 , 14, 1534-8	4	42
56	Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7491-6	2.2	360
55	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1055-62	2.2	924
54	Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. <i>Clinical Cancer Research</i> , 2004 , 10, 2029-34	12.9	234
53	Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 292, 1317-25	27.4	876
52	A protein truncating BRCA1 allele with a low penetrance of breast cancer. <i>Journal of Medical Genetics</i> , 2004 , 41, e130	5.8	11
51	Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1094-8	9.7	137
50	NBS1 is a prostate cancer susceptibility gene. <i>Cancer Research</i> , 2004 , 64, 1215-9	10.1	132
49	BRCA1 and BRCA2: 1994 and beyond. <i>Nature Reviews Cancer</i> , 2004 , 4, 665-76	31.3	694
48	Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. <i>Psycho-Oncology</i> , 2004 , 13, 14-25	3.9	85
47	Smoking and the risk of breast cancer among carriers of BRCA mutations. <i>International Journal of Cancer</i> , 2004 , 110, 413-6	7.5	40
46	Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2328-35	2.2	514
45	CHEK2 is a multiorgan cancer susceptibility gene. <i>American Journal of Human Genetics</i> , 2004 , 75, 1131-5	11	349
44	Improved survival in women with BRCA-associated ovarian carcinoma. <i>Cancer</i> , 2003 , 97, 2187-95	6.4	363

43	Hereditary ovarian cancer in Poland. <i>International Journal of Cancer</i> , 2003 , 106, 942-5	7.5	70
42	A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. <i>Human Mutation</i> , 2002 , 20, 352-7	4.7	55
41	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. <i>Nature Genetics</i> , 2002 , 31, 55-9	36.3	863
40	Modifiers of risk of hereditary breast and ovarian cancer. <i>Nature Reviews Cancer</i> , 2002 , 2, 113-23	31.3	139
39	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. <i>New England Journal of Medicine</i> , 2002 , 346, 1616-22	59.2	1363
38	Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1564-9	9.7	58
37	Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2002 , 14, 19-26	2.4	57
36	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 1773-9	9.7	266
35	What options for treatment of hereditary breast cancer?. <i>Lancet, The</i> , 2002 , 359, 1451-2	4.0	5
34	Hormonal prevention of hereditary breast cancer. <i>Annals of the New York Academy of Sciences</i> , 2001 , 952, 36-43	6.5	44
33	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. <i>American Journal of Human Genetics</i> , 2001 , 68, 700-10	11	809
32	Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. <i>Gynecologic Oncology</i> , 2000 , 79, 477-81	4.9	104
31	An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. <i>Journal of Medical Genetics</i> , 2000 , 37, 866-74	5.8	78
30	Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. <i>Preventive Medicine</i> , 2000 , 31, 75-80	4.3	224
29	Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. <i>American Journal of Human Genetics</i> , 2000 , 66, 1963-8	11	196
28	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. <i>Lancet, The</i> , 2000 , 356, 1876-81	4.0	473
27	BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. <i>American Journal of Human Genetics</i> , 2000 , 66, 1259-72	11	252
26	Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. <i>Clinical Genetics</i> , 1999 , 55, 318-24	4	45

25	Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. <i>Journal of the National Cancer Institute</i> , 1999 , 91, 1241-7	9.7	326
24	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome 1998 , 78, 386-387		3
23	Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. <i>Journal of the National Cancer Institute</i> , 1998 , 90, 761-6	9.7	104
22	Analysis of BRCA1 mutations in a Pakistani family with hereditary breast and ovarian cancer syndrome 1998 , 78, 386		1
21	BRCA2 hereditary breast cancer pathophenotype. <i>Breast Cancer Research and Treatment</i> , 1997 , 44, 275-7	4.4	59
20	Family with Graves disease, multinodular goiter, nonmedullary thyroid carcinoma, and alveolar rhabdomyosarcoma 1997 , 72, 30-33		2
19	Excess of congenital abnormalities in French-Canadian children with neuroblastoma: a case series study from Montréal. <i>Medical and Pediatric Oncology</i> , 1997 , 29, 272-9		15
18	A descriptive study of BRCA1 testing and reactions to disclosure of test results. <i>Cancer</i> , 1997 , 79, 2219-28	28.4	176
17	Hereditary breast carcinoma syndromes. <i>Cancer</i> , 1997 , 80, 537-542	6.4	5
16	BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. <i>Cancer</i> , 1997 , 80, 543-556	6.4	40
15	Pathology and genetic testing. <i>Cancer</i> , 1997 , 80, 636-648	6.4	1
14	CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. <i>International Journal of Cancer</i> , 1997 , 73, 531-6	7.5	37
13	Congenital anomalies and childhood cancer in Great Britain. <i>American Journal of Human Genetics</i> , 1997 , 60, 474-85	11	117
12	Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. <i>Nature Medicine</i> , 1996 , 2, 1179-83	50.5	253
11	The impact of family history on early detection of prostate cancer. <i>Nature Medicine</i> , 1995 , 1, 99-101	50.5	150
10	Androgen receptor and familial prostate cancer. <i>Nature Medicine</i> , 1995 , 1, 848-9	50.5	13
9	Identification of the breast cancer susceptibility gene BRCA2. <i>Nature</i> , 1995 , 378, 789-92	50.4	2780
8	Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: a case-control study. <i>International Journal of Cancer</i> , 1995 , 63, 769-73	7.5	83

7	An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. <i>American Journal of Human Genetics</i> , 1995 , 56, 254-64	11	177
6	Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. <i>Nature Genetics</i> , 1994 , 8, 392-8	36.3	285
5	A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> , 1994 , 266, 66-71	33.3	4991
4	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. <i>Lancet, The</i> , 1994 , 343, 692-5	40	1553
3	Genetics of breast and ovarian cancer. <i>British Medical Bulletin</i> , 1994 , 50, 656-76	5.4	18
2	Genetic heterogeneity of early-onset familial breast cancer. <i>Human Genetics</i> , 1992 , 89, 381-3	6.3	13
1	Power of the admixture test to detect genetic heterogeneity. <i>Genetic Epidemiology</i> , 1991 , 8, 209-16	2.6	2